Literature DB >> 12382522

Current management and prognostic factors for adult ependymoma.

Michele Reni1, Alba A Brandes.   

Abstract

The optimum therapeutic management in adult ependymoma remains undefined because of the low incidence of this disease and because most of reported series mainly refers to childhood, are retrospective, include a small number of patients and span several decades. The purpose of this article is to analyze, discuss and summarize the current available information regarding the therapeutic approach and the prognostic factors and to provide recommendations for ordinary clinical practice. Some important therapeutic issues like the irradiation dose and volume are also analyzed. Finally, the main open questions as well as current and expected investigation trends are discussed.

Entities:  

Mesh:

Year:  2002        PMID: 12382522     DOI: 10.1586/14737140.2.5.537

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  4 in total

1.  Symptoms and socio-economic impact of ependymoma on adult patients: results of the Adult Ependymoma Outcomes Project 2.

Authors:  Tobias Walbert; Tito R Mendoza; Elizabeth Vera-Bolaños; Alvina Acquaye; Mark R Gilbert; Terri S Armstrong
Journal:  J Neurooncol       Date:  2014-10-31       Impact factor: 4.130

2.  Local radiotherapeutic management of ependymomas with fractionated stereotactic radiotherapy (FSRT).

Authors:  Stephanie E Combs; Christoph Thilmann; Jürgen Debus; Daniela Schulz-Ertner
Journal:  BMC Cancer       Date:  2006-09-07       Impact factor: 4.430

3.  Fourth ventricular ependymoma with a distant intraventricular metastasis: Report of a rare case.

Authors:  Sudheer Ambekar; Manish Ranjan; Chandrajit Prasad; Vani Santosh; Sampath Somanna
Journal:  J Neurosci Rural Pract       Date:  2013-08

4.  PTEN R130Q Papillary Tumor of the Pineal Region (PTPR) with Chromosome 10 Loss Successfully Treated with Everolimus: A Case Report.

Authors:  Hazem I Assi; Rasha T Kakati; Juliett Berro; Ibrahim Saikali; Bassem Youssef; Roula Hourany; Ibrahim Alameh; Abeer Tabbarah; Jessica Khoury; Houssein Darwish; Saada Alame
Journal:  Curr Oncol       Date:  2021-03-20       Impact factor: 3.677

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.